UNIVERSITY BIRMINGHAM University of Birmingham Research at Birmingham

Sulfation pathways

Foster, Paul; Mueller, Jonathan Wolf

DOI: 10.1530/JME-18-0086

License: Other (please specify with Rights Statement)

Document Version Peer reviewed version

Citation for published version (Harvard):

Foster, P & Mueller, JW 2018, 'Sulfation pathways: Insights into steroid sulfation and desulfation pathways', *Journal of Molecular Endocrinology*, vol. 61, no. 2, pp. T271–T283. https://doi.org/10.1530/JME-18-0086

Link to publication on Research at Birmingham portal

Publisher Rights Statement:

Checked for eligibility: 25/05/2018

This is a pre-copyedited, author-produced version of an article accepted for publication in Endocrinology following peer review. The version of record Foster, P.A. and Mueller, J.W., 2018. SULFATION PATHWAYS: Insights into steroid sulfation and desulfation pathways. Journal of molecular endocrinology, 61(2), pp.T271-T283. is available online at: https://doi.org/10.1530/JME-18-0086

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)

•Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

1 Insights into Steroid Sulfation and Desulfation Pathways

- 2 Paul A Foster^{1,2} & Jonathan Wolf Mueller^{1,2}
- 3 ¹Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Edgbaston,
- 4 Birmingham B15 2TT, United Kingdom
- 5 ²Centre for Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham Health Partners,
- 6 Edgbaston, Birmingham B15 2TH, United Kingdom
- 7 Please address correspondence to PAF, <u>p.a.foster@bham.ac.uk</u>, or JWM, <u>j.w.mueller@bham.ac.uk</u>.

8 Abbreviations used:

- 9 25-OH-D3-S, 25-hydroxy-vitamin D3-3-sulfate; APS, adenosine-5'-phosphosulfate; DHEA,
- 10 dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; LC-MS/MS, liquid-
- 11 chromatography-tandem-mass-spectrometry; PAP, 3'-phospho-adenosine-5'-phosphate; PAPS, 3'-
- 12 phospho-adenosine-5'-phosphosulfate; PAPSS, 3'-phospho-adenosine-5'-phosphosulfate synthase;
- 13 STS, steroid sulfatase; SULT (1A1/1A3/2A1/1E1/18), sulfotransferase (1A1/1A3/2A1/1E1/18); TPST
- 14 (1/2), tyrosyl-protein sulfotransferase (1/2); XLI, X-linked ichthyosis

15 Abstract

16 Sulfation and desulfation pathways represent highly dynamic ways of shuttling, repressing and re-17 activating steroid hormones, thus controlling their immense biological potency at the very heart of 18 endocrinology. This theme currently experiences growing research interest from various sides, 19 including, but not limited to, novel insights about PAPS synthase and sulfotransferase function and 20 regulation, novel analytics for steroid conjugate detection and quantification. Within this review, we 21 will also define how sulfation pathways are ripe for drug development strategies, which have 22 translational potential to treat a number of conditions, including chronic inflammatory diseases and 23 steroid-dependent cancers.

24 Introduction

Steroid sulfation and desulfation pathways represent fundamental routes which regulate steroid circulatory transport and action. Whilst sulfated almost all steroids are inert and unable to bind to and activate their specific nuclear receptors. Indeed, as they are no longer lipophilic, sulfated steroids require active transport into cells via organic anion-transporters. Once intracellular, steroid conjugates can be desulfated, a process catalyzed by the ubiquitously expressed steroid sulfatase (STS) enzyme.

31 Over the past 50 years, scientific perspectives on why sulfated steroids exist have changed several 32 times, from it being a mere solubilization step for subsequent renal secretion to sulfated steroids 33 representing a dynamic pool of steroid precursors fueling peripheral steroid signaling (Reed, et al. 34 2005). Such dynamic sulfation/desulfation processes are highly relevant in the endocrine 35 communication between mother and fetus, a field that recently was reviewed elsewhere (Geyer, et 36 al. 2017). Another twist comes from recent evidence that sulfated steroids can still be substrates for 37 steroidogenic enzymes, suggesting they may act as hormonal precursors for a wide range of steroids. 38 We have previously provided a comprehensive review examining how sulfation and desulfation 39 impacts steroid action in normal physiology and in a multitude of disease states (Mueller, et al. 40 2015). Here we aim to give an update on the key advancements in this rapidly moving field.

41 Different PAPS synthases for different sulfation pathways?

42 PAPS synthases and a subset of sulfotransferases work together to ensure efficient sulfation of 43 steroid hormones. PAPS synthases provide high-energy sulfate in the form of 3'-phospho-adenosine-44 5'-phosphosulfate (PAPS) that is then used for sulfuryl transfer to hydroxyl- or amino-groups of 45 acceptor molecules (Mueller and Shafqat 2013). Several recent cell-based studies investigated the 46 function of PAPSS1. Small interfering RNA-mediated knockdown of PAPSS1 sensitizes non-small cell 47 lung cancer cells to DNA damaging agents (Leung, et al. 2015; Leung, et al. 2017). PAPSS1 further 48 seems to be essential for nuclear provirus establishment during retroviral (HIV) infection (Bruce, et 49 al. 2008). This was independent from tyrosine sulfation of the CCR5 co-receptor of HIV, but required 50 the sulfotransferase SULT1A1 for HIV-1 minus-strand DNA elongation (Swann, et al. 2016); however, 51 the authors left open what SULT1A1 substrate was responsible for this effect.

52 A different picture emerges for the functionality of PAPSS2, the only other PAPS synthase encoded in 53 the human genome. Transcriptional co-regulation of the *PAPSS2* genes with the SULT2A1 54 sulfotransferase has been reported in some cases (Kim, et al. 2004; Sonoda, et al. 2002). Generally, 55 *PAPSS2* is believed to be an inducible gene (Fuda, et al. 2002; Mueller et al. 2015); controlled by TGF-56 β via p38 kinase phosphorylating Sox9 (Coricor and Serra 2016). Rare compromising mutations in the 57 *PAPSS2* gene present clinically with bone and cartilage mal-formations and an endocrine defect 58 (Noordam, et al. 2009). By performing a DHEA challenge test, we established that inactivating 59 *PAPSS2* mutations cause apparent SULT2A1 deficiency (Oostdijk, et al. 2015). DHEA could no longer 60 be efficiently sulfated and was downstream converted to biologically active androgens; manifesting 61 with undetectable DHEA sulfate, androgen excess and metabolic disease (Oostdijk et al. 2015).

62 Mechanistically, it is difficult to explain why two highly conserved enzymes with an amino acid 63 identity of 78% could not compensate for each other. Both enzymes have similar APS kinase catalytic 64 activity (Grum, et al. 2010) and they both shuttle between cytoplasm and nucleus, controlled by 65 conserved nuclear localization and export signals (Schroder, et al. 2012). However, PAPS synthases 1 66 and 2 differ markedly in their protein stability, with PAPSS2 being partially unfolded at physiological 67 temperature (van den Boom, et al. 2012). The natural ligand and substrate adenosine-5'-68 phosphosulfate (APS) stabilizes the enzyme, making APS an efficient modulator of sulfation 69 pathways (Mueller and Shafgat 2013). For the sulfation pathways studied so far, the PAPS co-factor 70 is always rate-limiting (Kauffman 2004; Moldrup, et al. 2011); but the question remains how specificity for one of the PAPS synthases is generated. 71

72 Substrate specificity and regulation of sulfotransferases

Sulfotransferases provide specificity to sulfation reactions by means of binding specific subsets of 73 74 acceptor molecules (Coughtrie 2016). Our understanding of their structure, regulation, and function 75 within different sulfation pathways has significantly increased in recent years. The first crystal 76 structure of a plant sulfotransferase in complex with substrate, Arabidopsis SULT18/AtSOT18 with 77 the glucosinolate sinigrin bound to it, identified essential residues for substrate binding and 78 demonstrated that the catalytic mechanism may be conserved between human and plant 79 sulfotransferase enzymes (Hirschmann, et al. 2017). Further, the core elements including the 5'-PSB 80 and 3'-PB motifs, both involved in the binding of PAPS, are structurally conserved even in the 81 distantly related tyrosine-protein sulfotransferases, human TPST1 and TPST2 (Tanaka, et al. 2017; 82 Teramoto, et al. 2013). Protein substrates have to locally unfold and bind in a deep active site cleft 83 to TPSTs and the vicinity of the acceptor tyrosine residues adopts an intrinsically unfolded 84 conformation in order to facilitate this process (Tanaka et al. 2017; Teramoto et al. 2013). TPSTs 85 were known to fulfill different biological functions; shear stress applied to primary cultures of human 86 umbilical vein endothelial cells lead to downregulation of TPST1 via protein kinase C, but to upregulation of TPST2 via a tyrosine kinase-dependent pathway (Goettsch, et al. 2006; Goettsch, et 87 88 al. 2002). However, there are no obvious differences in the substrate-binding site of TPST1 and 2; 89 these need to be hidden in other non-conserved residues in the periphery. Similarly, substrate 90 specificity may be controlled outside of the active center for Arabidopsis SULT18/SOT18 91 (Hirschmann et al. 2017). The substrate specificity of human SULT1A3, on the other hand, is well 92 understood. A single amino acid substitution in the substrate binding site (glutamic acid at position 93 146) makes SULT1A3 highly selective for catecholamines (both endogenous and xenobiotic) as 94 Glu146 forms a salt bridge with the nitrogen on the catecholamine side chain (Dajani, et al. 1999). 95 With this one exception, the molecular understanding of the isoform specificity of sulfotransferases 96 remains a challenge despite the wealth of structural information.

97 Recent insights into enzyme kinetics may be helpful here. It is well known that sulfotransferases can 98 show substrate-inhibition due to the formation of non-productive ternary complexes (Gulcan and 99 Duffel 2011; Mueller et al. 2015). More recent is the view that sulfotransferases may be allosterically 100 regulated by their cofactor PAPS: This allosteric regulation extended the dynamic range of SULT1A1's 101 catalytic efficiency (Wang, et al. 2014). Certainly, a new concept is that sulfotransferases might be 102 allosterically regulated in an isozyme-specific manner; liver sulfotransferase SULT1A1 for example is 103 modulated by catechins (naturally occurring polyphenols) and nonsteroidal anti-inflammatory drugs 104 (Wang, et al. 2016). All these modes of regulation of SULTs are illustrated in Figure 1. A better 105 understanding of sulfotransferase enzymes may have direct translational potential for drug 106 development (Cook, et al. 2016): Raloxifene is an approved selective estrogen receptor modulator 107 that is quickly sulfated, and thus inactivated, in human cells. Modulating this compound in a way 108 that prevented sulfation, but left its interaction with the estrogen receptor untouched, resulted in an enormous increase in estrogen receptor-activation efficacy (Cook et al. 2016). It is likely that this 109 110 approach could also work with other compounds.

111 Finally, it is population genetics influencing steroid sulfation pathways and the interindividual 112 variability in drug response. Several coding single nucleotide polymorphisms in SULT genes influence 113 an individual's sulfation capacity (Louwers, et al. 2013), but also gene number variations have been 114 reported for SULT2A1 (Ekstrom and Rane 2015) and other sulfotransferases (Marto, et al. 2017). In 115 fact, the SULT2A1 gene seems to be more evolvable than, for example, PAPS synthases (Mueller et 116 al. 2015); Ensembl (https://www.ensembl.org) lists various expansions of this gene in different 117 lineages with an eight-genes-comprising gene cluster in mice (Zerbino, et al. 2018), while a set of 118 two PAPS synthase genes is highly conserved in vertebrates (van den Boom et al. 2012). A reverse 119 approach using metabolomics and pharmacogenomics indicated that acetaminophen use 120 phenocopied the effect of genetic variants of SULT2A1 on sulfated metabolites of androstenediol, 121 pregnenolone, and DHEA (Cohen, et al. 2018). This study also challenges views on the mechanism of 122 action of acetaminophen in pain management as sulfated sex hormones can function as 123 neurosteroids and modify nociceptive thresholds.

124 Analytics of steroid conjugates

125 From the very beginning of steroid metabolomics, steroid mixtures were de-conjugated before 126 analysis, mainly by gas-chromatography-mass-spectrometry (Shackleton 2010). However, measuring 127 both free and conjugated steroids may give complementary information. Quantification of 128 conjugates could be laboriously carried out using biochemical separation techniques (Shackleton, et 129 al. 1968) or in multi-step differential de-conjugation measurements (Hill, et al. 2010). 130 Experimentally, detection of intact steroid conjugates was reported already in 1982 (Shackleton and 131 Straub 1982), using particle beam ionization; however this technique did not become standard in 132 analytical labs. Only recently, more and more reports describe the targeted measurements of steroid 133 sulfates and glucuronides using LC-MS/MS. Galuska et al. (Galuska, et al. 2013) reported a combined 134 targeted method for intact steroid sulfates and unconjugated steroids. Six steroid sulfates were 135 quantified by ESI-MS-MS in negative mode and, separately, 11 unconjugated steroids were analyzed 136 by atmospheric pressure chemical ionization (APCI)-MS-MS in positive mode. This combined method 137 could be used for different biological matrices including aqueous solutions, cell lysates and serum 138 (Galuska et al. 2013). Validated targeted LC-MS/MS assays for different sex steroid sulfates from 139 human serum are becoming available (Dury, et al. 2015; Poschner, et al. 2017; Sanchez-Guijo, et al. 140 2015b). Nevertheless, all these assays require separate runs for the conjugated and free steroids. An 141 integrated method for quantifying free and sulfated steroids in a single LC-MS/MS run was recently 142 described (Lee, et al. 2016). It used both SIM and MRM modes as well as polarity switching and was 143 capable of detecting eight free steroids and four sulfated ones. All methods described so far, were 144 targeted assays.

145 Noteworthy, low-energy collision-induced dissociation may be a way to discover new sulfo-146 conjugates. Maekawa et al. (Maekawa, et al. 2014) used this technique not only to detect sulfate

147 adducts (-97 m/z), but also glycine (-74 m/z) or taurine conjugates. The group of Oscar Pozo 148 developed a modification of this idea to monitor disulfates (McLeod, et al. 2017); these doubly 149 sulfated steroids will be discussed further below. Constant-ion-loss monitoring of one of the sulfates 150 (-97 m/z) allowed untargeted detection of potentially all soluble bis-sulfates; with the caveat that 151 phosphates could also cause this signal (McLeod et al. 2017). This method was recently applied in 152 prenatal diagnostics [Pozo et al, J Mol Endocr, accepted 19-Feb-2018]. Further developments in 153 steroid conjugate analytics may involve ultra-high-performance supercritical-fluid chromatography 154 linked to mass spectrometry (Doue, et al. 2015) and mass spectrometry-imaging as established for 155 sulfated gluco-lipids (Marsching, et al. 2014) or for testosterone (Shimma, et al. 2016); allowing for 156 spatial resolution of sulfation ratios.

157 Measuring sulfation ratios of different enzymes precisely might help to expand what has been called 158 the "sulfated steroid pathway" (Sanchez-Guijo, et al. 2016). The concept that sulfation does not 159 prevent downstream conversion of steroids, but modulates it, is based on the side-chain cleaving 160 activity of cytochrome P450 CYP11A1 towards cholesterol sulfate (Tuckey 1990). This observation 161 was then extended to CYP17A1 that bound and metabolized pregnenolone sulfate (Neunzig, et al. 162 2014). It is STS that can then convert sulfated steroids to biologically active steroids (Sanchez-Guijo 163 et al. 2016). Steroid analysis of patients with steroid sulfatase deficiency suggests that other 164 enzymes partially can complement STS (Sanchez-Guijo et al. 2016). In such a pathway, the sulfo-165 group acts as protection group, allowing downstream biochemical conversions on one side of the 166 steroid molecule, but not on the other.

167 Selected steroid species in sulfo-focus

168 Several steroid conjugates have been known for decades, but only recently have these forms been

thought to be biologically meaningful and worth studying. Here, we briefly review knowledge about

170 vitamin D-sulfates, steroid disulfates and 11-oxo-androgens.

171 Vitamin D

172 25-hydroxy-vitamin D3-3-sulfate (25-OH-D3-S) is a major metabolite of vitamin D3 found in the 173 systemic circulation (Axelson 1985). As circulating concentrations of 25OH-D3-3-O-sulfate seem not 174 to be rapidly secreted by the kidney, there is the possibility that this sulfate metabolite may serve as 175 a reservoir of 250H-D3 in vivo, contributing indirectly to the biologic effects of vitamin D (Wong, et 176 al. 2018). Sulfotransferase SULT2A1 was identified as the major vitamin D3-sulfating enzyme (Kurogi, 177 et al. 2017; Wong et al. 2018). SULT2A1 showed activity towards several vitamin D3-related 178 compounds, whereas SULT1A1 and SULT2B1a/SULT2B1b only showed sulfating activity for, 179 respectively, calcitriol and 7-dehydrocholesterol (Kurogi et al. 2017).

The relationship between vitamin D and sulfation pathways is reciprocal. The vitamin D receptor also induces transcription of the steroid sulfotransferases *SULT2A1* (Echchgadda, et al. 2004) and *SULT2B1b* (Seo, et al. 2013) as well as the phase I monooxygenase *CYP3A4* (Ahn, et al. 2016), among other genes. Interestingly, the induction of steroid sulfatase by vitamin D3 and retinoids was reported in HL60 promyeloid cells (Hughes, et al. 2001). As net effect, vitamin D transcriptional regulation results in androgen inactivation (Ahn et al. 2016) and elevated sulfation activity that might increase the levels of vitamin D sulfate metabolites.

Several analytical methods have been reported to detect and quantify vitamin D3 sulfoconjugates
(Abu Kassim, et al. 2018; Gao, et al. 2017; Higashi, et al. 2014). Axelson reported values of 35±14 nM
for 25-hydroxy-D3-3-sulfate in plasma from 60 patients (Axelson 1985), Gao measured 56±24 nM for

190 25-OH-D3-3-sulfate in serum from six healthy volunteers (Gao et al. 2017) and Abu Kassim found a 191 range of 9.52-43.8 nM for 25-OH-D3-3-sulfate in serum of 10 volunteers (Abu Kassim et al. 2018). 192 Concentrations of this vitamin D3 sulfoconjugate were consistently higher than its glucuronidated 193 counterparts. More importantly, the reported circulating concentrations for vitamin D3-3-sulfate 194 reach up to what is regarded as the normal level of circulating 25-OH-vitamin D3, 80-250 nM (Hollis 195 2010). Early studies described vitamin D3-3-sulfate as less biologically active than free vitamin D3 in 196 rodents (Cancela, et al. 1987; Nagubandi, et al. 1981). Considering the high circulating 197 concentrations of 25-OH-D3-3-sulfate in the human circulation, it should be taken into account when 198 determining a person's vitamin D status - it could be a reservoir for local generation of 25-OH-D3 and 199 the active 1,25-di-OH-D3.

200 Steroid disulfates

201 Several steroid-diols like estradiol or androstenediol can be doubly sulfated, most likely by the same 202 steroid sulfotransferases due to the pseudo-symmetry of those steroids (Mueller et al. 2015) and a 203 high degree of plasticity in the substrate binding sites (Berger, et al. 2011). As early as in 1962, 204 steroid disulfates (also referred to as bis-sulfates) were described as a constituent of human urine 205 (Pasgualini and Jayle 1962). Falany and coworkers established for 24-hydroxycholesterol-3,24-206 disulfate that double sulfation leads to a terminal product that is resistant to re-activation by STS 207 (Cook, et al. 2009). This fueled the idea that a second sulfation step represented a further regulatory 208 step or an irreversible step towards inactivation (Mueller et al. 2015). Double sulfation also changes 209 affinity for organic anion transporters. While estradiol-3-sulfate and estradiol-17-sulfate both were 210 substrates for the sodium-dependent organic anion transporter SOAT (SLC10A6), estradiol-3,17-211 disulfate no longer was cargo for this transporter (Grosser, et al. 2017); depending on where the 212 second sulfation step may occur within the cell, a steroid disulfate may be confined to that cellular 213 compartment.

214 11-oxo androgenic steroids

215 The C19 steroid 11β -hydroxy-androstenedione is produced by the adrenal in significant amounts; it 216 has however long been regarded as a dead-end product of adrenal steroidogenesis (Pretorius, et al. 217 2017). In recent years, evidence has accumulated that this steroid could be converted to potent 218 androgenic 11-oxygenated steroids, 11-keto-testosterone and 11-keto-dihydrotestosterone, that 219 have similar potency to testosterone and dihydrotestosterone to activate the human androgen 220 receptor (Storbeck, et al. 2013). Sulfated 11-oxo-steroids have not been reported until now, 221 analogous to other androgens (Schiffer, et al. 2018). Interestingly, 11-oxo-steroids seem to be 222 resistant to glucuronidation in various cancer cell lines (du Toit and Swart 2018) and 11-keto-223 testosterone and 11-keto-dihydrotestosterone are metabolized at a slower rate than testosterone 224 and dihydrotestosterone (Pretorius, et al. 2016). It seems that the 11-oxo modification prevents 225 conjugation, making these steroids to exert prolonged androgenic effects.

226 Steroid sulfatase action and regulation

Steroid sulfatase is a membrane-bound protein with its active site located in the lumen of the endoplasmic reticulum (Thomas and Potter 2013). It catalyzes the hydrolysis of sulfate ester bonds from many chemical structures, and it is heavily involved in the desulfation of steroids. STS's main hormone substrates are estrone sulfate, dehydroepiandrosterone sulfate (DHEAS), pregnenolone sulfate, and cholesterol sulfate. Thus, STS action represents a major intracrine route in regenerating biologically active steroids. The crystal structure of STS has been determined (Hernandez-Guzman, et al. 2003) showing a domain consisting of two antiparallel α -helices that protrude from the roughly spherical structure; this gives it a "mushroom-like" shape. Despite this, very little is known on what factors regulate STS activity. STS undergoes post-translational modifications, the key one being the generation of C-alpha formylglycine (FGly), the catalytic residue in the active site of STS, from a cysteine by sulfatase-modifying factors 1 and 2 (SUMF1 & SUMF2). Furthermore, STS contains four potential N-glycosylation sites, however only two (Asn47 and Asn259) are used (Stein, et al. 1989; von Figura, et al. 1998) and only mutations at these sites decrease activity (Stengel, et al. 2008).

240 Most recent studies have focused on directly measuring STS activity in a range of diseases and 241 conditions in order to shed some light on how this enzyme is molecularly controlled (see Figure 2). 242 Evidence from chronic liver disease and pre-osteoblastic cells suggests inflammatory mediators, in 243 particularly TNFα (Newman, et al. 2000), can regulate STS expression and activity most likely through 244 NF-kB signaling (Dias and Selcer 2016; Jiang, et al. 2016); with activity depressed by glucocorticoid 245 treatment (Dias and Selcer 2016). Interestingly, estrogens have also been shown to influence STS activity in leukocytes taken from pregnant patients where STS activity is increased in the 3rd 246 247 trimester (Miyakawa, et al. 1994). In support of this, Gilligan et al. have shown estradiol (E_2) treatment can increase STS activity in colorectal cancer cells via G-protein coupled estrogen receptor 248 249 (GPER) action (Gilligan, et al. 2017a). These studies suggest a potential positive feedback mechanism 250 by which elevated local estrogen synthesis can further drive estrogen desulfation and activity. How 251 this system is controlled by down-stream GPER mediators remains unknown. However, it is of 252 interest that many steroids, including estrogens, are anti-inflammatory and thus local 253 sulfation/desulfation regulation may represent a mechanism by which steroids control the local 254 influence of an inflammatory insult.

255 Mutations in the STS gene and X-linked Ichthyosis

256 Mutations or deletions of the STS gene result in X-linked ichthyosis (XLI), a condition associated with 257 hyperkeratosis (Ballabio, et al. 1989). XLI is also termed STS deficiency and represents a common 258 inherited metabolic disorder, with 1:6000 live births and no geographical or ethnical variation 259 (Fernandes, et al. 2010). Patients with XLI have no sulfatase activity and thus cholesterol sulfate 260 breakdown is impaired. The subsequent cholesterol sulfate accumulation physiologically stabilizes 261 cell membranes (Williams 1992) and builds-up in the stratum corneum causing partial retention 262 hyperkeratosis with visible scaling (Elias, et al. 1984; Williams and Elias 1981). With this loss of 263 desulfation, it is reasonable to assume XLI patients would also exhibit depleted circulating desulfated 264 steroid concentrations, which would subsequently effect their hormone-related development. 265 However, in healthy adult men STS has no significant impact on systemic androgen reactivation from 266 DHEAS (Hammer, et al. 2005), thus suggesting STS loss has less physiological effects than anticipated. 267 Indeed, in XLI patients, a compensatory mechanism has been identified through the upregulation of 268 5α -reductase which, the authors suggest, maintains peripheral and rogen activation despite reduced 269 androgen availability (Idkowiak, et al. 2016). Along with changes in androgen metabolism, XLI 270 patients also have elevated plasma concentrations of 27-hydroxycholesterol-3-sulfate compared to 271 healthy males (Sanchez-Guijo, et al. 2015a). The effects of this increased oxysterol sulfate remains 272 unknown.

Greater than 90% of XLI patients harbor complete deletions of the *STS* gene. However, there have been 14 point mutations within the *STS* gene previously reported; 3 nonsense mutations and 11 missense mutations (Mueller et al. 2015). More recently, a mutation in exon 3 of the *STS* gene was shown to cause a complete loss of STS activity in the affected patient (del Refugio Rivera Vega, et al. 2015). Furthermore, two unrelated Japanese patients with ichthyosis are known to have two different point mutations in exon 7 (Oyama, et al. 2016). A novel indel mutation in exon 5 of the *STS* 279 gene has also been reported leading to a frameshift causing a premature stop codon 81 codons 280 downstream from the substitution site (Takeichi, et al. 2015). Intriguingly, this frameshift did not 281 affect the reported active site of STS thus the encoded transcript may be spared if a truncated 282 mutant protein was synthesized.

283 Steroid Sulfatase and Cancer

284 Breast Cancer

285 The most exciting advancements in steroid desulfation research have come through two recently 286 completed clinical trials of the STS inhibitor Irosustat (STX64, 667Coumate). The IPET trial examined 287 Irosustat in treatment of naive ER+ early breast cancer patients (Palmieri, et al. 2017b) and the 288 Phase II IRIS trial examining the clinical benefit rate of Irosustat combined with aromatase inhibition 289 in advance and metastatic ER+ breast cancer (Palmieri, et al. 2017a). Although patient recruitment 290 numbers were relatively low (IPET n = 13; IRIS n = 27) both trials demonstrated some clinical benefit 291 for STS inhibition. In the IPET trial breast tumors were assessed for the effects of Irosustat on tumor 292 growth as measured by 3'-deoxy-3'-[18F]-fluorothymidine uptake measured by PET scanning (FLT-293 PET) and Ki67 immunohistochemistry. STS inhibition significantly reduced Ki67 scores and the tumor 294 uptake of FLT as measured by PET. Furthermore, Irosustat also decreased tumor STS expression, 295 with this effect also observed in other estrogen metabolizing enzymes and ERa expression. This 296 suggests STS inhibition may have beneficial effects with regards to dampening down tumor estrogen 297 synthesis.

298 Previous pre-clinical studies have shown combining aromatase inhibitors with STS inhibition was a 299 viable strategy to treat MCF-7 xenografts in mice (Foster, et al. 2008a). Thus, the IRIS trial testing this 300 strategy in breast cancer patients who had lapsed whilst on aromatase therapy. Clinical benefit rate 301 was seen in 18.5% (95% Cl 6.3-38.1%) of patients with a median progression-free survival of 2.7 302 months (95% Cl 2.5-4.6). Considering the difficulty of treating advanced and metastatic breast 303 cancer, these results are encouraging for the future of STS inhibition in breast cancer treatment. 304 Furthermore, MCF-7 cells resistant to letrozole treatment have been shown to have higher STS 305 mRNA expression and greater expression of organic anion-transporting polypeptides, which mediate 306 estrone sulfate transport into the cell (Higuchi, et al. 2016). This provides some molecular insight 307 into aromatase resistance and how STS inhibition may be beneficial to patients who relapse on 308 aromatase inhibitors. However, more clinical data is still required to examine whether Irosustat, or 309 indeed other STS inhibitors, would be beneficial for ER+ aromatase resistant breast cancer patients.

310 Gynecological Cancers

311 Along with new evidence suggesting the importance of STS and SULT1E1 expression in endometriosis 312 (Piccinato, et al. 2016), there are new insights into how desulfation impacts endometrial (Sinreih, et 313 al. 2017) and ovarian (Mungenast, et al. 2017; Ren, et al. 2015) cancers. This work represents a 314 growing interest in local estrogen metabolism and action in gynecological conditions (Rizner 2016; 315 Rizner, et al. 2017). Indeed, these studies show a lack of aromatase activity and expression in these 316 cancers, implicating STS activity as the most likely pathway through which local estrogen synthesis 317 occurs (Ren et al. 2015; Sinreih et al. 2017). Indeed, high SULT1E1 protein expression is positively 318 associated with better-differentiated epithelial ovarian cancers compared to grade 3 epithelial 319 ovarian cancers (Mungenast et al. 2017). This suggests estrogen sulfation, and thus inactivation, 320 limits estrogen tissue availability reducing the potential mitogenic effects of non-sulfated estrogens. 321 Thus, targeting desulfation (i.e. via STS inhibition) may be an important strategy in treating ovarian 322 and endometrial cancer. Pre-clinical mouse xenograft studies have previously demonstrated that STS inhibition blocks estrone sulfate stimulated growth of endometrial tumors (Foster, et al. 2008b),
although this theory remains to be tested clinically. Furthermore, and if the STS pathway dominates
estrogen synthesis, then these studies may go some way to explain the clinical failure of aromatase

326 inhibitors to treat endometrial cancer (Bogliolo, et al. 2016).

327 Gastrointestinal Cancers

328 A growing body of evidence on gastrointestinal cancers now implicates sex steroids and their 329 desulfation as important drivers of proliferation (Barzi, et al. 2013; Foster 2013; Ur Rahman and Cao 330 2016). Most research has focused on colorectal cancer (CRC) as previous work has shown a potential prognostic role for STS and SULT1E1 protein expression in CRC (Sato, et al. 2009), implicating a high 331 332 STS and low SULT1E1 expression as indicative of a poor outcome. More recently, over-expression of 333 STS in the CRC cell line HCT116 increases proliferation in vitro and in vivo xenograft mouse models, 334 with these effects blocked by STS inhibition by STX64 (Gilligan, et al. 2017b). These actions were 335 shown to be through increased estrogen desulfation and activation of the G-protein coupled 336 estrogen receptor (GPER), a finding further supported by evidence these effects may be modulated 337 by a hypoxic environment (Bustos, et al. 2017). Indeed, it is of interest to note STS activity can 338 increase hypoxia inducible factor Hif1 α expression in cervical and prostate cancer cells, suggesting 339 STS action may be further regulated by hypoxic conditions (Shin, et al. 2017). Furthermore, estradiol 340 (E2) treatment increases both STS activity (Gilligan et al. 2017a) and GPER expression in CRC (Bustos 341 et al. 2017), suggesting a novel positive feedback loop through which E_2 can drive CRC proliferation.

342 Steroid sulfation pathways, the brain and behavior

343 XLI patients have an association with behavioral disorders, which include attention deficit-344 hyperactivity disorder (ADHD), autism, and social communication deficits (Davies, et al. 2009; 345 Stergiakouli, et al. 2011). A study examining 384 patients with ADHD identified two SNPs in the STS 346 gene significantly associated with this condition (Brookes, et al. 2008). Indeed, the polymorphism 347 rs17268988 within the STS gene is associated with inattentive behavior in males with ADHD (Humby, 348 et al. 2017). More recently, XLI patients have been shown to be at a significantly increased risk of 349 developmental conditions and psychiatric illness (Chatterjee, et al. 2016). The hormonal implications 350 in these conditions remains ill-defined, although researchers have hypothesized disturbed neuronal 351 DHEA-DHEAS metabolism might result in altered neurotransmitter function contributing to the 352 observed abnormalities. There is some support for this theory, albeit in a different disease context. 353 Evidence suggests declining concentrations of neurosteroids, such as DHEA and DHEAS, are closely 354 associated with increased risk of Alzheimer's disease (AD) (El Bitar, et al. 2014; Wojtal, et al. 2006). 355 STS inhibition attenuated cognitive deficits in spatial learning and memory and in hippocampal 356 synaptic plasticity in rats with amyloid β protein induced AD (Yue, et al. 2016). The authors suggest 357 STS inhibition elevated brain DHEAS concentrations with this accounting for the neuroprotective 358 effects, although neuronal DHEAS levels were not measured. Thus, definitive proof that DHEAS is the 359 key neurosteroid linked to STS action within the brain remains to be seen.

Another sulfated steroid, pregnenolone sulfate, is known to inhibit GABA neurotransmission in the brain. Two new studies shed light on the effect of this and other neurosteroids on GABA(A) receptor function. The stimulating neurosteroids tetra-hydrodeoxycorticosteron (THDOC) and pregnanolone bind to the very same site within the transmembrane domain (Laverty, et al. 2017; Miller, et al. 2017). Inhibitory pregnenolone-sulfate on the other hand binds to another site within the transmembrane domain and fosters pore opening, which corresponds to the desensitized state (Laverty et al. 2017). 367

368 Conclusion

369 Despite this review only covering the past few years of steroid sulfation and desulfation research, it

- 370 highlights the now strong evidence supporting the importance on sulfation and desulfation
- 371 pathways in controlling steroid action. Most importantly, early clinical trials in hormone-dependent
- breast cancer of the STS inhibitor Irosustat are encouraging and suggest inhibiting desulfation as a
- 373 viable strategy. Thus, targeting steroid desulfation in other cancers and conditions remains of
- significant interest. Furthermore, improvements in measuring both sulfated and non-sulfated
- 375 steroids via mass spectrometry should allow for more sensitive quantification and thus a greater
- ability to tease-out how the balance between sulfation and desulfation is regulated.
- However, there is still much we do not know. Defining which PAPS synthase interacts with which
- 378 SULT would lead to a greater understanding on steroid sulfation pathways and may lend itself to
- 379 specific inhibitory strategies. Most researchers in this area focus on sulfated estrogens and androgen
- 380 precursors (e.g. DHEAS), however we have little grasp of whether other sulfated steroids, such as
- 381 vitamin D, represent biologically relevant reservoirs for local desulfation and subsequent action.
- 382 Furthermore, we are only beginning to understand about disulfated steroids, and at present, we do
- not know how these are formed and whether they possess biological function. Finally, we still do not
- clearly understand what factors regulate STS activity, although inflammation seems most likely toplay a role.

386 Acknowledgement

- 387 We acknowledge Martin Hewison and Karl Storbeck for reading and commenting on some parts of
- this manuscript. Research in the area of this review was funded by the European Commission (Marie
- Curie Fellowship SUPA-HD 625451, to JWM), the Wellcome Trust (ISSF award, to JWM), the MRC
- 390 (Proximity-to-Discovery, to PAF and JWM) and the Society for Endocrinology (Early Career Grants, to
- 391 JWM and PAF; Themed Scientific Meeting Grant, to PAF and JWM).

392 Declaration of interest

- 393 The authors declare that there is no conflict of interest that could be perceived as prejudicing the
- impartiality of the research reported.

395 References

- Abu Kassim NS, Shaw PN & Hewavitharana AK 2018 Simultaneous determination of 12 vitamin D
 compounds in human serum using online sample preparation and liquid chromatography tandem mass spectrometry. J Chromatogr A 1533 57-65.
- Ahn J, Park S, Zuniga B, Bera A, Song CS & Chatterjee B 2016 Vitamin D in Prostate Cancer. *Vitam Horm* 100 321-355.
- 401 Axelson M 1985 25-Hydroxyvitamin D3 3-sulphate is a major circulating form of vitamin D in man.
 402 *FEBS Lett* **191** 171-175.
- Ballabio A, Carrozzo R, Parenti G, Gil A, Zollo M, Persico MG, Gillard E, Affara N, Yates J, FergusonSmith MA, et al. 1989 Molecular heterogeneity of steroid sulfatase deficiency: a multicenter
 study on 57 unrelated patients, at DNA and protein levels. *Genomics* 4 36-40.

406 Barzi A, Lenz AM, Labonte MJ & Lenz HJ 2013 Molecular pathways: Estrogen pathway in colorectal 407 cancer. Clin Cancer Res 19 5842-5848. 408 Berger I, Guttman C, Amar D, Zarivach R & Aharoni A 2011 The molecular basis for the broad 409 substrate specificity of human sulfotransferase 1A1. PLoS One 6 e26794. 410 Bogliolo S, Gardella B, Dominoni M, Musacchi V, Cassani C, Zanellini F, De Silvestri A, Gaggero CR, 411 Babilonti L & Spinillo A 2016 Effectiveness of aromatase inhibitors in the treatment of 412 advanced endometrial adenocarcinoma. Arch Gynecol Obstet 293 701-708. 413 Brookes KJ, Hawi Z, Kirley A, Barry E, Gill M & Kent L 2008 Association of the steroid sulfatase (STS) 414 gene with attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 415 147B 1531-1535. 416 Bruce JW, Ahlquist P & Young JA 2008 The host cell sulfonation pathway contributes to retroviral 417 infection at a step coincident with provirus establishment. PLoS Pathog 4 e1000207. 418 Bustos V, Nolan AM, Nijhuis A, Harvey H, Parker A, Poulsom R, McBryan J, Thomas W, Silver A & 419 Harvey BJ 2017 GPER mediates differential effects of estrogen on colon cancer cell 420 proliferation and migration under normoxic and hypoxic conditions. Oncotarget 8 84258-421 84275. 422 Cancela L, Marie PJ, Le Boulch N & Miravet L 1987 Lack of biological activity of vitamin D3-3 beta 423 sulfate during lactation in vitamin D-deficient rats. Reprod Nutr Dev 27 979-997. 424 Chatterjee S, Humby T & Davies W 2016 Behavioural and Psychiatric Phenotypes in Men and Boys 425 with X-Linked Ichthyosis: Evidence from a Worldwide Online Survey. PLoS One 11 e0164417. 426 Cohen IV, Cirulli ET, Mitchell MW, Jonsson TJ, Yu J, Shah N, Spector TD, Guo L, Venter JC & Telenti A 427 2018 Acetaminophen (Paracetamol) Use Modifies the Sulfation of Sex Hormones. 428 EBioMedicine 28 316-323. 429 Cook I, Wang T, Wang W, Kopp F, Wu P & Leyh TS 2016 Controlling Sulfuryl-Transfer Biology. Cell 430 Chem Biol 23 579-586. 431 Cook IT, Duniec-Dmuchowski Z, Kocarek TA, Runge-Morris M & Falany CN 2009 24-432 hydroxycholesterol sulfation by human cytosolic sulfotransferases: formation of monosulfates 433 and disulfates, molecular modeling, sulfatase sensitivity, and inhibition of liver x receptor 434 activation. Drug Metab Dispos 37 2069-2078. 435 Coricor G & Serra R 2016 TGF-beta regulates phosphorylation and stabilization of Sox9 protein in 436 chondrocytes through p38 and Smad dependent mechanisms. Sci Rep 6 38616. 437 Coughtrie MWH 2016 Function and organization of the human cytosolic sulfotransferase (SULT) 438 family. Chem Biol Interact 259 2-7. 439 Dajani R, Cleasby A, Neu M, Wonacott AJ, Jhoti H, Hood AM, Modi S, Hersey A, Taskinen J, Cooke 440 RM, et al. 1999 X-ray crystal structure of human dopamine sulfotransferase, SULT1A3. 441 Molecular modeling and quantitative structure-activity relationship analysis demonstrate a 442 molecular basis for sulfotransferase substrate specificity. J Biol Chem 274 37862-37868. 443 Davies W, Humby T, Kong W, Otter T, Burgoyne PS & Wilkinson LS 2009 Converging pharmacological 444 and genetic evidence indicates a role for steroid sulfatase in attention. Biol Psychiatry 66 360-445 367. 446 del Refugio Rivera Vega M, Murillo-Vilches MR, Toral-Lopez J, Sanchez EG, Sanchez AT, Gonzalez-447 Huerta LM & Cuevas-Covarrubias SA 2015 X-linked ichthyosis in a patient with a novel 448 nonsense mutation in the STS gene. J Dermatol Sci 80 160-162. 449 Dias NJ & Selcer KW 2016 Steroid sulfatase in the human MG-63 preosteoblastic cell line: 450 Antagonistic regulation by glucocorticoids and NFkappaB. Mol Cell Endocrinol 420 85-96. 451 Doue M, Dervilly-Pinel G, Pouponneau K, Monteau F & Le Bizec B 2015 Analysis of glucuronide and 452 sulfate steroids in urine by ultra-high-performance supercritical-fluid chromatography 453 hyphenated tandem mass spectrometry. Anal Bioanal Chem 407 4473-4484. du Toit T & Swart AC 2018 Inefficient UGT-conjugation of adrenal 11beta-hydroxyandrostenedione 454 455 metabolites highlights C11-oxy C19 steroids as the predominant androgens in prostate cancer. 456 Mol Cell Endocrinol 461 265-276.

457 Dury AY, Ke Y, Gonthier R, Isabelle M, Simard JN & Labrie F 2015 Validated LC-MS/MS simultaneous 458 assay of five sex steroid/neurosteroid-related sulfates in human serum. J Steroid Biochem Mol 459 Biol 149 1-10. 460 Echchgadda I, Song CS, Roy AK & Chatterjee B 2004 Dehydroepiandrosterone sulfotransferase is a 461 target for transcriptional induction by the vitamin D receptor. Mol Pharmacol 65 720-729. 462 Ekstrom L & Rane A 2015 Genetic variation, expression and ontogeny of sulfotransferase SULT2A1 in 463 humans. Pharmacogenomics J 15 293-297. 464 El Bitar F, Meunier J, Villard V, Almeras M, Krishnan K, Covey DF, Maurice T & Akwa Y 2014 465 Neuroprotection by the synthetic neurosteroid enantiomers ent-PREGS and ent-DHEAS 466 against Abeta(2)(5)(-)(3)(5) peptide-induced toxicity in vitro and in vivo in mice. 467 Psychopharmacology (Berl) 231 3293-3312. 468 Elias PM, Williams ML, Maloney ME, Bonifas JA, Brown BE, Grayson S & Epstein EH, Jr. 1984 Stratum 469 corneum lipids in disorders of cornification. Steroid sulfatase and cholesterol sulfate in normal 470 desquamation and the pathogenesis of recessive X-linked ichthyosis. J Clin Invest 74 1414-471 1421. 472 Fernandes NF, Janniger CK & Schwartz RA 2010 X-linked ichthyosis: an oculocutaneous 473 genodermatosis. J Am Acad Dermatol 62 480-485. 474 Foster PA 2013 Oestrogen and colorectal cancer: mechanisms and controversies. Int J Colorectal Dis 475 **28** 737-749. 476 Foster PA, Chander SK, Newman SP, Woo LW, Sutcliffe OB, Bubert C, Zhou D, Chen S, Potter BV, 477 Reed MJ, et al. 2008a A new therapeutic strategy against hormone-dependent breast cancer: 478 the preclinical development of a dual aromatase and sulfatase inhibitor. Clin Cancer Res 14 479 6469-6477. 480 Foster PA, Woo LW, Potter BV, Reed MJ & Purohit A 2008b The use of steroid sulfatase inhibitors as 481 a novel therapeutic strategy against hormone-dependent endometrial cancer. Endocrinology 482 149 4035-4042. 483 Fuda H, Shimizu C, Lee YC, Akita H & Strott CA 2002 Characterization and expression of human 484 bifunctional 3'-phosphoadenosine 5'-phosphosulphate synthase isoforms. Biochem J 365 497-485 504. 486 Galuska CE, Hartmann MF, Sanchez-Guijo A, Bakhaus K, Geyer J, Schuler G, Zimmer KP & Wudy SA 487 2013 Profiling intact steroid sulfates and unconjugated steroids in biological fluids by liquid 488 chromatography-tandem mass spectrometry (LC-MS-MS). Analyst 138 3792-3801. 489 Gao C, Bergagnini-Kolev MC, Liao MZ, Wang Z, Wong T, Calamia JC, Lin YS, Mao Q & Thummel KE 490 2017 Simultaneous quantification of 25-hydroxyvitamin D3-3-sulfate and 25-hydroxyvitamin 491 D3-3-glucuronide in human serum and plasma using liquid chromatography-tandem mass 492 spectrometry coupled with DAPTAD-derivatization. J Chromatogr B Analyt Technol Biomed Life 493 Sci 1060 158-165. 494 Geyer J, Bakhaus K, Bernhardt R, Blaschka C, Dezhkam Y, Fietz D, Grosser G, Hartmann K, Hartmann 495 MF, Neunzig J, et al. 2017 The role of sulfated steroid hormones in reproductive processes. J 496 Steroid Biochem Mol Biol 172 207-221. 497 Gilligan LC, Gondal A, Tang V, Hussain MT, Arvaniti A, Hewitt AM & Foster PA 2017a Estrone Sulfate 498 Transport and Steroid Sulfatase Activity in Colorectal Cancer: Implications for Hormone 499 Replacement Therapy. Front Pharmacol 8 103. 500 Gilligan LC, Rahman HP, Hewitt AM, Sitch AJ, Gondal A, Arvaniti A, Taylor AE, Read ML, Morton DG & 501 Foster PA 2017b Estrogen Activation by Steroid Sulfatase Increases Colorectal Cancer 502 Proliferation via GPER. J Clin Endocrinol Metab 102 4435-4447. 503 Goettsch S, Badea RA, Mueller JW, Wotzlaw C, Schoelermann B, Schulz L, Rabiller M, Bayer P & 504 Hartmann-Fatu C 2006 Human TPST1 transmembrane domain triggers enzyme dimerisation 505 and localisation to the Golgi compartment. J Mol Biol 361 436-449.

506 507	Goettsch S, Goettsch W, Morawietz H & Bayer P 2002 Shear stress mediates tyrosylprotein sulfotransferase isoform shift in human endothelial cells. <i>Biochem Biophys Res Commun</i> 294
508	541-546.
509	Grosser G, Bennien J, Sanchez-Guijo A, Bakhaus K, Doring B, Hartmann M, Wudy SA & Geyer J 2017
510	Transport of steroid 3-sulfates and steroid 17-sulfates by the sodium-dependent organic anion
511	transporter SOAT (SLC10A6). J Steroid Biochem Mol Biol.
512	Grum D, van den Boom J, Neumann D, Matena A, Link NM & Mueller JW 2010 A heterodimer of
513	human 3'-phospho-adenosine-5'-phosphosulphate (PAPS) synthases is a new sulphate
514	activating complex. Biochem Biophys Res Commun 395 420-425.
515	Gulcan HO & Duffel MW 2011 Substrate inhibition in human hydroxysteroid sulfotransferase
516	SULT2A1: studies on the formation of catalytically non-productive enzyme complexes. Arch
517	Biochem Biophys 507 232-240.
518	Hammer F, Subtil S, Lux P, Maser-Gluth C, Stewart PM, Allolio B & Arlt W 2005 No evidence for
519	hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA: in vivo and in vitro
520	studies. <i>J Clin Endocrinol Metab</i> 90 3600-3605.
521	Hernandez-Guzman FG, Higashiyama T, Pangborn W, Osawa Y & Ghosh D 2003 Structure of human
522	estrone sulfatase suggests functional roles of membrane association. J Biol Chem 278 22989-
523	22997.
524	Higashi T, Goto A, Morohashi M, Ogawa S, Komatsu K, Sugiura T, Fukuoka T & Mitamura K 2014
525	Development and validation of a method for determination of plasma 25-hydroxyvitamin D3
526	3-sulfate using liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt
527	Technol Biomed Life Sci 969 230-234.
528	Higuchi T, Endo M, Hanamura T, Gohno T, Niwa T, Yamaguchi Y, Horiguchi J & Hayashi S 2016
529	Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant,
530	Hormone Receptor-Positive Breast Cancer. PLoS One 11 e0155844.
531	Hill M, Parizek A, Cibula D, Kancheva R, Jirasek JE, Jirkovska M, Velikova M, Kubatova J, Klimkova M,
532	Paskova A, et al. 2010 Steroid metabolome in fetal and maternal body fluids in human late
533	pregnancy. J Steroid Biochem Mol Biol 122 114-132.
534	Hirschmann F, Krause F, Baruch P, Chizhov I, Mueller JW, Manstein DJ, Papenbrock J & Fedorov R
535	2017 Structural and biochemical studies of sulphotransferase 18 from Arabidopsis thaliana
536	explain its substrate specificity and reaction mechanism. Sci Rep 7 4160.
537	Hollis BW 2010 Assessment and interpretation of circulating 25-hydroxyvitamin D and 1,25-
538	dihydroxyvitamin D in the clinical environment. Endocrinol Metab Clin North Am 39 271-286,
539	table of contents.
540	Hughes PJ, Twist LE, Durham J, Choudhry MA, Drayson M, Chandraratha R, Michell RH, Kirk CJ &
541	Brown G 2001 Op-regulation of steroid sulphatase activity in HL60 promyelocytic cells by
542	retinoids and Taipna,25-dinydroxyvitamin D3. <i>Biochem J</i> 355 361-371.
543	Humby I, Fisher A, Allen C, Reynolds M, Hartman A, Glegling I, Rujescu D & Davies W 2017 A genetic
544	variant within STS previously associated with inattention in boys with attention deficit
545	nyperactivity disorder is associated with enhanced cognition in healthy adult males. Brain
546	Benav 7 eulos 46.
547	Idkowlak J, Taylor AE, Subtil S, O'Nell DM, Vijzelaar R, Dias RP, Amin R, Barrett TG, Snackleton CH,
548	Kirk JW, et al. 2016 Sterold Sulfatase Deficiency and Androgen Activation Before and After
549	PUDERTY, J Clin Endocrinol Metab 101 2545-2553.
	Jiang IVI, Kielin IVI, Zanger Olivi, IVIOnanimau IVIK, Cave IVIC, Galkwad INW, Dias IVJ, Seičer KW, Guo Y, He
221	J, et al. 2010 Initial Initiatory regulation of Sterold Suffaces A novel mechanism to control astrogen homoestasic and inflammation in chronic liver disease. J Henstel 64 44, 52
552 552	escrugen nonneoscasis and initialinitiation in chronic liver disease. J Hepatol 64 44-52. Kauffman EC 2004 Sulfonation in pharmacology and toyicology. Drug Match Pay 26 822-842
555	Kaumman FC 2004 Sumonation in priamacology and toxicology. <i>Drug Mietub Rev</i> 30 623-843.
555	(Sult2A1) during the acute nhase response Am I Dhysiol Endocrinol Metah 297 E721 729
555	עמונצחדן ממוווא נווב מכמנב-phase ובשטוושב. אוווש דוושטוטו בוומטנוווטו ואובנמט 201 ב151-750.

556 Kurogi K, Sakakibara Y, Suiko M & Liu MC 2017 Sulfation of vitamin D3 -related compounds-557 identification and characterization of the responsible human cytosolic sulfotransferases. FEBS 558 Lett 591 2417-2425. 559 Laverty D, Thomas P, Field M, Andersen OJ, Gold MG, Biggin PC, Gielen M & Smart TG 2017 Crystal 560 structures of a GABAA-receptor chimera reveal new endogenous neurosteroid-binding sites. 561 Nat Struct Mol Biol 24 977-985. 562 Lee SH, Lee N, Hong Y, Chung BC & Choi MH 2016 Simultaneous Analysis of Free and Sulfated 563 Steroids by Liquid Chromatography/Mass Spectrometry with Selective Mass Spectrometric 564 Scan Modes and Polarity Switching. Anal Chem 88 11624-11630. 565 Leung AW, Dragowska WH, Ricaurte D, Kwok B, Mathew V, Roosendaal J, Ahluwalia A, Warburton C, 566 Laskin JJ, Stirling PC, et al. 2015 3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) 567 knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents. Oncotarget 6 568 17161-17177. 569 Leung AWY, Veinotte CJ, Melong N, Oh MH, Chen K, Enfield KSS, Backstrom I, Warburton C, Yapp D, 570 Berman JN, et al. 2017 In Vivo Validation of PAPSS1 (3'-phosphoadenosine 5'-phosphosulfate 571 synthase 1) as a Cisplatin-sensitizing Therapeutic Target. Clin Cancer Res 23 6555-6566. 572 Louwers YV, de Jong FH, van Herwaarden NA, Stolk L, Fauser BC, Uitterlinden AG & Laven JS 2013 573 Variants in SULT2A1 affect the DHEA sulphate to DHEA ratio in patients with polycystic ovary 574 syndrome but not the hyperandrogenic phenotype. J Clin Endocrinol Metab 98 3848-3855. 575 Maekawa M, Shimada M, Iida T, Goto J & Mano N 2014 Tandem mass spectrometric characterization 576 of bile acids and steroid conjugates based on low-energy collision-induced dissociation. 577 Steroids 80 80-91. 578 Marsching C, Jennemann R, Heilig R, Grone HJ, Hopf C & Sandhoff R 2014 Quantitative imaging mass 579 spectrometry of renal sulfatides: validation by classical mass spectrometric methods. J Lipid 580 Res 55 2343-2353. 581 Marto N, Morello J, Monteiro EC & Pereira SA 2017 Implications of sulfotransferase activity in 582 interindividual variability in drug response: clinical perspective on current knowledge. Drug 583 Metab Rev 49 357-371. 584 McLeod MD, Waller CC, Esquivel A, Balcells G, Ventura R, Segura J & Pozo OJ 2017 Constant Ion Loss 585 Method for the Untargeted Detection of Bis-sulfate Metabolites. Anal Chem 89 1602-1609. 586 Miller PS, Scott S, Masiulis S, De Colibus L, Pardon E, Steyaert J & Aricescu AR 2017 Structural basis 587 for GABAA receptor potentiation by neurosteroids. Nat Struct Mol Biol 24 986-992. 588 Miyakawa I, Kawano Y, Taniyama K & Mori N 1994 Steroid sulfatase activity in human leukocytes. 589 Gynecol Obstet Invest 38 191-193. 590 Moldrup ME, Geu-Flores F, Olsen CE & Halkier BA 2011 Modulation of sulfur metabolism enables 591 efficient glucosinolate engineering. BMC Biotechnol 11 12. 592 Mueller JW 2018 Hormongesteuert – neue molekulare Erkenntnisse. In BIOspektrum, p 57. 593 Mueller JW, Gilligan LC, Idkowiak J, Arlt W & Foster PA 2015 The Regulation of Steroid Action by 594 Sulfation and Desulfation. Endocr Rev 36 526-563. 595 Mueller JW & Shafqat N 2013 Adenosine-5'-phosphosulfate--a multifaceted modulator of 596 bifunctional 3'-phospho-adenosine-5'-phosphosulfate synthases and related enzymes. FEBS J 597 **280** 3050-3057. 598 Mungenast F, Aust S, Vergote I, Vanderstichele A, Sehouli J, Braicu E, Mahner S, Castillo-Tong DC, 599 Zeillinger R & Thalhammer T 2017 Clinical significance of the estrogen-modifying enzymes 600 steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer. Oncol Lett 13 601 4047-4054. 602 Nagubandi S, Londowski JM, Bollman S, Tietz P & Kumar R 1981 Synthesis and biological activity of 603 vitamin D3 3 beta-sulfate. Role of vitamin D3 sulfates in calcium homeostasis. J Biol Chem 256 604 5536-5539.

605	Neunzig J, Sanchez-Guijo A, Mosa A, Hartmann MF, Geyer J, Wudy SA & Bernhardt R 2014 A
606	steroidogenic pathway for sulfonated steroids: the metabolism of pregnenolone sulfate. J
607	Steroid Biochem Mol Biol 144 Pt B 324-333.
608	Newman SP, Purohit A, Ghilchik MW, Potter BV & Reed MJ 2000 Regulation of steroid sulphatase
609	expression and activity in breast cancer. J Steroid Biochem Mol Biol 75 259-264.
610	Noordam C, Dhir V, McNelis JC, Schlereth F, Hanley NA, Krone N, Smeitink JA, Smeets R, Sweep FC,
611	Claahsen-van der Grinten HL, et al. 2009 Inactivating PAPSS2 mutations in a patient with
612	premature pubarche. N Engl J Med 360 2310-2318.
613	Oostdijk W, Idkowiak J, Mueller JW, House PJ, Taylor AE, O'Reilly MW, Hughes BA, de Vries MC, Kant
614	SG, Santen GW, et al. 2015 PAPSS2 deficiency causes androgen excess via impaired DHEA
615	sulfationin vitro and in vivo studies in a family harboring two novel PAPSS2 mutations. J Clin
616	Endocrinol Metab 100 E672-680.
617	Oyama N, Matsuda M, Hamada T, Numata S, Teye K, Hashimoto T & Hasegawa M 2016 Two novel
618	missense mutations of STS gene underlie X-linked recessive ichthyosis: understanding of the
619	mutational and structural spectrum. J Eur Acad Dermatol Venereol 30 1629-1631.
620	Palmieri C, Stein RC, Liu X, Hudson E, Nicholas H, Sasano H, Guestini F, Holcombe C, Barrett S, Kenny
621	L, et al. 2017a IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when
622	added to an aromatase inhibitor in ER-positive breast cancer patients. Breast Cancer Res Treat
623	165 343-353.
624	Palmieri C, Szydlo R, Miller M, Barker L, Patel NH, Sasano H, Barwick T, Tam H, Hadjiminas D, Lee J, et
625	al. 2017b IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase
626	inhibitor irosustat in early breast cancer. Breast Cancer Res Treat 166 527-539.
627	Pasqualini JR & Jayle MF 1962 Identification of 3beta,21-dihydroxy-5-pregnene-20-one disulfate in
628	human urine. J Clin Invest 41 981-987.
629	Piccinato CA, Neme RM, Torres N, Sanches LR, Derogis P, Brudniewski HF, Rosa ESJC & Ferriani RA
630	2016 Effects of steroid hormone on estrogen sulfotransferase and on steroid sulfatase
631	expression in endometriosis tissue and stromal cells. J Steroid Biochem Mol Biol 158 117-126.
632	Poschner S, Zehl M, Maier-Salamon A & Jager W 2017 Simultaneous quantification of estrogens,
633	their precursors and conjugated metabolites in human breast cancer cells by LC-HRMS
634	without derivatization. J Pharm Biomed Anal 138 344-350.
635	Pretorius E, Africander DJ, Vlok M, Perkins MS, Quanson J & Storbeck KH 2016 11-Ketotestosterone
636	and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens
637	Which Can No Longer Be Ignored. <i>PLoS One</i> 11 e0159867.
638	Pretorius E, Arlt W & Storbeck KH 2017 A new dawn for androgens: Novel lessons from 11-
639	oxygenated C19 steroids. Mol Cell Endocrinol 441 76-85.
640	Reed MJ, Purohit A, Woo LW, Newman SP & Potter BV 2005 Steroid sulfatase: molecular biology,
641	regulation, and inhibition. Endocr Rev 26 171-202.
642	Ren X, Wu X, Hillier SG, Fegan KS, Critchley HO, Mason JI, Sarvi S & Harlow CR 2015 Local estrogen
643	metabolism in epithelial ovarian cancer suggests novel targets for therapy. J Steroid Biochem
644	Mol Biol 150 54-63.
645	Rizner TL 2016 The Important Roles of Steroid Sulfatase and Sulfotransferases in Gynecological
646	Diseases. Front Pharmacol 7 30.
647	Rizner TL, Thalhammer T & Ozvegy-Laczka C 2017 The Importance of Steroid Uptake and Intracrine
648	Action in Endometrial and Ovarian Cancers. Front Pharmacol 8 346.
649	Sanchez-Guijo A, Neunzig J, Gerber A, Oji V, Hartmann MF, Schuppe HC, Traupe H, Bernhardt R &
650	Wudy SA 2016 Role of steroid sulfatase in steroid homeostasis and characterization of the
651	sulfated steroid pathway: Evidence from steroid sulfatase deficiency. Mol Cell Endocrinol 437
652	142-153.
653	Sanchez-Guijo A, Oji V, Hartmann MF, Schuppe HC, Traupe H & Wudy SA 2015a High levels of
654	oxysterol sulfates in serum of patients with steroid sulfatase deficiency. J Lipid Res 56 403-412.

655	Sanchez-Guijo A, Oji V, Hartmann MF, Traupe H & Wudy SA 2015b Simultaneous quantification of
656	cholesterol sulfate, androgen sulfates, and progestagen sulfates in human serum by LC-
657	MS/MS. J Lipid Res 56 1843-1851.
658	Sato R, Suzuki T, Katayose Y, Miura K, Shiiba K, Tateno H, Miki Y, Akahira J, Kamogawa Y, Nagasaki S,
659	et al. 2009 Steroid sulfatase and estrogen sulfotransferase in colon carcinoma: regulators of
660	intratumoral estrogen concentrations and potent prognostic factors. Cancer Res 69 914-922.
661	Schiffer L, Arlt W & Storbeck KH 2018 Intracrine androgen biosynthesis, metabolism and action
662	revisited. Mol Cell Endocrinol 465 4-26.
663	Schroder E, Gebel L, Eremeev AA, Morgner J, Grum D, Knauer SK, Bayer P & Mueller JW 2012 Human
664	PAPS synthase isoforms are dynamically regulated enzymes with access to nucleus and
665	cytoplasm. PLoS One 7 e29559.
666	Seo YK, Mirkheshti N, Song CS, Kim S, Dodds S, Ahn SC, Christy B, Mendez-Meza R, Ittmann MM,
667	Abboud-Werner S, et al. 2013 SULT2B1b sulfotransferase: induction by vitamin D receptor and
668	reduced expression in prostate cancer. <i>Mol Endocrinol</i> 27 925-939.
669	Shackleton C 2010 Clinical steroid mass spectrometry: a 45-year history culminating in HPLC-MS/MS
670	becoming an essential tool for patient diagnosis. J Steroid Biochem Mol Biol 121 481-490.
671	Shackleton CH. Livingstone IR & Mitchell FI 1968 The conjugated 17-hydroxy enimers of delta5-
672	androstene-3heta-17-diol in infant and adult urine and umbilical cord plasma. Steroids 11 299-
673	311
674	Shackleton CH & Straub KM 1982 Direct analysis of steroid conjugates: the use of secondary jon
675	mass spectrometry. Steroids 40 35-51
676	Shimma S. Kumada HO. Taniguchi H. Konno A. Vao I. Euruta K. Matsuda T.& Ito S. 2016 Microsconic
677	visualization of testosterone in mouse testis by use of imaging mass spectrometry. Anal
678	Riognal Chem 408 7607-7615
670	Shin Silm HI, Kwon XI, Vo DI, Book HS, Kim D, Choi HK & Chun XI 2017 Human storoid sulfatasa
680	induces Wet /bota categoing and enitbolial mesonshumal transition by upregulating
000 601	Twist1 and HIE 1alpha in human prostate and convical cancer cells. Once target 9 61604 61617
601	Since h M. Knifie T. Anko M. Hovir N. Vouk K. Jorin A. Erkovic Crozic S. 8. Dizpor T. 2017 The
602	Simelin W, Kimic T, Aiko W, Hevir N, Vouk K, Jenni A, Fikovic Gldzio S & Kiziler TL 2017 The
003	Significance of the Sundlase Pathway for Local Estrogen Formation in Endometrial Cancer.
004	FIGHT PHUTHUCO & 500.
005	Solidua J, Xie W, Rosellielu JW, Barwick JL, Guzellall PS & Evalis Rivi 2002 Regulation of a Xenobiolic
000	suitoriation cascade by nuclear pregnane x receptor (PXR). Proc Nati Acdu Sci U S A 99 13801-
687	13800. Stein C. Wille A. Seidel J. Dünkenst S. Makend A. Sekwidt D. Seven U. S. von Figure K 1000 Clearing and
688	Stein C, Hille A, Seidel J, Rijnbout S, Waneed A, Schmidt B, Geuze H & von Figura K 1989 Cloning and
689	expression of numan steroid-suitatase. Membrane topology, glycosylation, and subcellular
690	distribution in BHK-21 cells. <i>J Biol Chem</i> 264 13865-13872.
691	Stengel C, Newman SP, Day JM, Tutill HJ, Reed MJ & Puronit A 2008 Effects of mutations and
692	giveosylations on STS activity: a site-directed mutagenesis study. <i>Wol Cell Endocrinol</i> 283 76-
693	
694	Stergiakouli E, Langley K, Williams H, Walters J, Williams NM, Suren S, Giegling I, Wilkinson LS, Owen
695	MJ, O'Donovan MC, et al. 2011 Steroid sulfatase is a potential modifier of cognition in
696	attention deficit hyperactivity disorder. Genes Brain Behav 10 334-344.
697	Storbeck KH, Bloem LM, Africander D, Schloms L, Swart P & Swart AC 2013 11beta-
698	Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with
699	androgenic activity: a putative role in castration resistant prostate cancer? Mol Cell Endocrinol
700	377 135-146.
701	Swann J, Murry J & Young JA 2016 Cytosolic sulfotransferase 1A1 regulates HIV-1 minus-strand DNA
702	elongation in primary human monocyte-derived macrophages. Virol J 13 30.
703	Takeichi T, Sugiura K, Hsu CK, Tanahashi K, Takama H, Simpson MA, McGrath JA & Akiyama M 2015
704	Novel indel mutation of STS underlies a new phenotype of self-healing recessive X-linked
705	ichthyosis. J Dermatol Sci 79 317-319.

706 Tanaka S, Nishiyori T, Kojo H, Otsubo R, Tsuruta M, Kurogi K, Liu MC, Suiko M, Sakakibara Y & Kakuta 707 Y 2017 Structural basis for the broad substrate specificity of the human tyrosylprotein 708 sulfotransferase-1. Sci Rep 7 8776. 709 Teramoto T, Fujikawa Y, Kawaguchi Y, Kurogi K, Soejima M, Adachi R, Nakanishi Y, Mishiro-Sato E, Liu 710 MC, Sakakibara Y, et al. 2013 Crystal structure of human tyrosylprotein sulfotransferase-2 711 reveals the mechanism of protein tyrosine sulfation reaction. Nat Commun 4 1572. 712 Thomas MP & Potter BV 2013 The structural biology of oestrogen metabolism. J Steroid Biochem 713 Mol Biol 137 27-49. 714 Tuckey RC 1990 Side-chain cleavage of cholesterol sulfate by ovarian mitochondria. J Steroid 715 Biochem Mol Biol 37 121-127. 716 Ur Rahman MS & Cao J 2016 Estrogen receptors in gastric cancer: Advances and perspectives. World 717 J Gastroenterol 22 2475-2482. 718 van den Boom J, Heider D, Martin SR, Pastore A & Mueller JW 2012 3'-Phosphoadenosine 5'-719 phosphosulfate (PAPS) synthases, naturally fragile enzymes specifically stabilized by 720 nucleotide binding. J Biol Chem 287 17645-17655. 721 von Figura K, Schmidt B, Selmer T & Dierks T 1998 A novel protein modification generating an 722 aldehyde group in sulfatases: its role in catalysis and disease. *Bioessays* 20 505-510. 723 Wang T, Cook I & Leyh TS 2014 3'-Phosphoadenosine 5'-phosphosulfate allosterically regulates 724 sulfotransferase turnover. Biochemistry 53 6893-6900. 725 Wang T, Cook I & Leyh TS 2016 Isozyme Specific Allosteric Regulation of Human Sulfotransferase 726 1A1. Biochemistry 55 4036-4046. 727 Williams ML 1992 Epidermal lipids and scaling diseases of the skin. Semin Dermatol 11 169-175. 728 Williams ML & Elias PM 1981 Stratum corneum lipids in disorders of cornification: increased 729 cholesterol sulfate content of stratum corneum in recessive x-linked ichthyosis. J Clin Invest 68 730 1404-1410. 731 Wojtal K, Trojnar MK & Czuczwar SJ 2006 Endogenous neuroprotective factors: neurosteroids. 732 Pharmacol Rep 58 335-340. 733 Wong T, Wang Z, Chapron BD, Suzuki M, Claw KG, Gao C, Foti RS, Prasad B, Chapron A, Calamia J, et 734 al. 2018 Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-735 Hydroxyvitamin D3-3-O-Sulfate, a Major Circulating Vitamin D Metabolite in Humans. Drug 736 Metab Dispos 46 367-379. 737 Yue XH, Tong JQ, Wang ZJ, Zhang J, Liu X, Liu XJ, Cai HY & Qi JS 2016 Steroid sulfatase inhibitor DU-14 738 protects spatial memory and synaptic plasticity from disruption by amyloid beta protein in 739 male rats. Horm Behav 83 83-92. 740 Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, Billis K, Cummins C, Gall A, Giron 741 CG, et al. 2018 Ensembl 2018. Nucleic Acids Res 46 D754-D761.

742

1 Figure legends

2

Figure 1: Different modes of regulation of sulfotransferase enzymes. A, human SULT1A3 contains a
 unique glutamate (E) in the substrate binding site, specifically binding catecholamines. B, substrates
 can bind in non-productive conformations, causing substrate inhibition. C, dissociation of PAP from
 the sulfotransferase may be rate-limiting, causing product inhibition. D, allosteric protein-protein
 contacts may regulate SULT function. E, non-substrate molecules may allosterically activate
 sulfotransferases. Please refer to the main text for further explanation.

9

10 Figure 2: The regulation of STS activity. Many factors are known to either increase or decrease STS 11 activity. To increase STS activity, sulfatase-modifying factors 1 and 2 (SUMF1 and SUMF2) generate 12 C-alpha formylglycine (FGIy), the catalytic residue in the active site of STS, from a cysteine. 13 Estrogens, in particular estradiol, have been shown to increase STS activity in leukocytes in the third 14 trimester of pregnancy and in colorectal cancer cells, with this effect potentially regulated by G-15 protein coupled estrogen receptors (GPER). Inflammation, mediated by TNF α through NF- κ B signalling, also increases local STS activity. Many cancers, in particular breast, prostate, and 16 colorectal cancer, have all been shown to have higher STS activity compared to non-malignant 17 18 tissue. Factors that decrease STS activity include mutations in the SUMF1 gene leading to failure of 19 the formation of FGly and thus reduced catalytic activity. Drugs, such as Irosustat, that target STS

20 activity have been developed. Interestingly, glucocorticoids, including dexamethasone, can reduce

21 STS activity in various cell lines. Inherited STS deficient (X-linked ichthyosis) patients have loss of STS

22 activity.

23





170x129mm (300 x 300 DPI)



Figure 2

318x221mm (96 x 96 DPI)